Axitinib 5mg
| Product Overview | |
| Generic Name | Axitinib 5mg |
| Brand Name(s) | INLYTA®; LENKLYRA |
| Product Type | Originator Brand |
| Form | 60 Film-coated oral tablets |
| Strength | 5mg |
| Therapeutic Class | VEGFR tyrosine kinase inhibitor / protein kinase inhibitor. |
| ATC Code | L01EK01 |
| Manufacturing & Regulatory | |
| Manufacturer | Pfizer, |
| Country | Germany |
| GMP Compliance | FDA/EMA/WHO-GMP |
| COFEPRIS | 010.000.6006.00 |
| Free Sale Certificate | Yes, available as COPP/CPP |
| Logistics & Export | |
| MOQ | 5 units |
| Shelf Life | 24 Months |
| Storage | Store at 20–25 °C |
| Incoterms | EXW, HSN 30049099 |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Manufacturer provides COA |
| CTD Summary | Not public; request Module 2 / ACTD summary |
Description
Axitinib is an oral VEGFR tyrosine kinase inhibitor used for advanced renal cell carcinoma. Current Pfizer labeling includes use in combination with avelumab or pembrolizumab for first-line advanced RCC, and also prior-systemic-therapy settings depending on jurisdiction and label version.
